lifestyle.californiaconsumerbanking.com

Author: Senti Biosciences, Inc.

Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase

May 14, 2026
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program

May 14, 2026
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

May 6, 2026
Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies

May 4, 2026
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

May 4, 2026
Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference

May 3, 2026
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

April 29, 2026
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

April 28, 2026
Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development

March 11, 2026
Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

March 10, 2026